This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Translocase of outer mitochondrial membrane 40 homolog (TOMM40)	<p>A genomewide association study suggests that variants in <i>TOMM40</i> could predict AD risk. In 172 AD patients and 209 controls, three SNP variants in <i>TOMM40</i> correlated with a disease-associated decrease in hippocampal volume as measured by MRI ($p=7.48 \times 10^{-7}$–1.10×10^{-3}). Next steps could include using this information to stratify patients in AD trials by <i>TOMM40</i> genotype.</p> <p>Zinfandel Pharmaceuticals Inc. is enrolling a Phase II prophylactic AD trial on an undisclosed compound in carriers of risk-associated <i>TOMM40</i> variants.</p> <p>SciBX 2(34); doi:10.1038/scibx.2009.1323 Published online Sept. 3, 2009</p>	Patent and licensing status undisclosed	<p>Potkin, S. <i>et al. PLoS One</i>; published online Aug. 7, 2009; doi:10.1371/journal.pone.0006501</p> <p>Contact: Steven G. Potkin, University of California, Irvine, Calif. e-mail: sgpotkin@uci.edu</p>